Female genital tract melanoma: The evidence is only skin deep

Current Opinion in Obstetrics and Gynecology

Volumn 17, Issue 1, 2005, Pages 1-4

  Rodriguez, Anne O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; CISPLATIN; DACARBAZINE; GANGLIOSIDE GM2; IMMUNOSTIMULATING AGENT; INTERFERON; INTERLEUKIN 2; LACTATE DEHYDROGENASE; MONOCLONAL ANTIBODY;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; EDITORIAL; FEMALE; FEMALE GENITAL TRACT CANCER; HIGH RISK PATIENT; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA; MORBIDITY; PRIORITY JOURNAL; PROGNOSIS; RARE DISEASE; SENTINEL LYMPH NODE BIOPSY; TREATMENT INDICATION; TUMOR VOLUME; VAGINA MELANOMA; VULVA MELANOMA;

EID: 14644439870     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200502000-00002     Document Type: Editorial

References (19)

1. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base Report on cutaneous and noncutaneous melanoma. Cancer 1998; 83:1664-1678.
2. Weinstock MA. Gynecology: malignant melanoma of the vulva and vagina in the United States: patterns of incidence and population-based estimates of survival. Am J Obstet Gynecol 1994; 171:1225-1230.
3. Balch CM, Buzaid AC, Soong SJ, et al. New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol 2003; 21:43-52.
4. de Braud F, Khayat D, Kroon BBR, et al. Malignant melanoma. Crit Rev Oncol/Hematol 2003; 47:35-63.
5. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351:998-1012.
6. Pawlik TM, Sondak VK. Malignant melanoma: current state of primary and adjuvant treatment. Crit Rev Oncol/Hematol 2003; 45:245-264.
7. Pavlick AC, Adams S, Fink MA, Bailes A. Novel therapeutic agents under investigation for malignant melanoma. Expert Opin Invest Drugs 2003; 12:1545-1558.
8. Livingston PO, Wong GY, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM ganglioside. J Clin Oncol 1944; 12:1036-1044.
9. Hersey P. Advances in the non-surgical treatment of melanoma. Expert Opin Invest Drugs 2002; 11:75-85.
10. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-2116.
11. Morrow CP, Curtin JP. Synopsis of gynecologic oncology. 5th ed. New York: Churchill Livingstone; 1998.
12. Phillips GL, Bundy BN, Okagaki T, et al. Malignant melanoma of the vulva treated by radical hemivulvectomy. Cancer 1994; 73:2626-2632.
13. Irvin WP, Legallo RL, Stoler MH, et al. Vulvar melanoma: a retrospective analysis and literature review. Gynecol Oncol 2001; 83:457-465.
14. Abramova L, Parekh J, Irvin WP, et al. Sentinel node biopsy in vulvar and vaginal melanoma: presentation of six cases and a literature review. Ann Surg Oncol 2002; 9:840-846.
15. Wechter ME, Gruber SB, Haefner HK, et al. Vulvar melanoma: a report of 20 cases and review of the literature. J Am Acad Dermatol 2004; 50:554-562.
16. Buchanan DJ, Schlaerth J, Kurosaki T. Primary vaginal melanoma: thirteen-year disease-free survival wide local excision and review of the literature. Am J Obstet Gynecol 1998; 178:1177-1184.
17. Miner TJ, Delgado R, Zeisler J, et al. Primary vaginal melanoma: a critical analysis of therapy. Ann Surg Oncol 2004; 11:34-39.
18. Wang Y, Chang W, Pu D. Clinical analysis of 15 patients with primary malignant melanoma in the genital tract. Zhonghua Fu Chan Ke Za Zhi 1997; 32:226-228.
19. Brand E, Fu YS, Lagasse LD, Berek JS. Vulvovaginal melanoma: report of seven cases and literature review. Gynecol Oncol 1989; 33:54-60.